期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥联合奥沙利铂治疗老年晚期结肠癌的疗效观察 被引量：7

下载PDF
导出
摘要 43例晚期结肠癌患者随机分为观察组:替吉奥+奥沙利铂联合化疗,对照组:m FOLFOX6方案化疗。观察两组患者的近期疗效及不良反应。两组患者的有效率比较无统计学差异(P>0.05),两组患者在骨髓抑制等方面差异无统计学意义(P>0.05),但腹泻,恶心,呕吐等消化道反应观察组低于对照组,差异具有统计学意义(P<0.05)。替吉奥联合奥沙利铂在老年晚期结肠癌中疗效确切,毒副反应低。
作者 胡迎宾 徐骏 况晶茹 熊华杰 游勇飞
机构地区 南昌市第一医院肿瘤科
出处 《现代诊断与治疗》 CAS 2015年第23期5340-5341,共2页 Modern Diagnosis and Treatment
关键词 替吉奥 奥沙利铂 老年 结肠癌
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献5

二级参考文献66

  • 1郭颖英,方伟虹,谢淑萍.替吉奥联合奥沙利铂治疗进展期胃癌疗效观察[J].浙江中医药大学学报,2010,34(5):783-783. 被引量：22
  • 2[1]Golfinopoulos V,Salanti G,Pavlidis N,et al.Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer:A meta-analysis.Lancet Oncol,2007,8(10):898
  • 3[2]Delaunoit T,Alberts SR,Sargent DJ,et al.Chemotherapy permits resection of metastatic colorectal cancer:Experience from Intergroup N9741.Ann Oncol,2005,16(3):425
  • 4[3]Nordlinger B,Sorbye H,Collette L,et al.Final results of the EORTC Intergroup randomized phase Ⅲ study 40983 (EPOC) evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases.J Clin Oncol,2007,25 (18S):LBA5
  • 5[4]Porschen R,Arkenau HT,Kubicka S,et al.Phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:A final report of the AIO Colorectal Study Group.J Clin Oncol,2007,25(27):4217
  • 6[5]Diaz-Rubio E,Tabernero J,Gomez-Espana A,et al.Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.J Clin Oncol,2007,25(27):4224
  • 7[6]Cassidy J,Clarke S,Diaz-Rubio E,et al.XELOX compared to FOLFOX4:Survival and response results from XELOX-1/NO16966,a randomized phase Ⅲ trial of first-line treatment for patients with metastatic colorectal cancer (MCRC).J Clin Oncol,2007,25(18S):4030abstr
  • 8[7]Rothenberg ML,Navarro M,Butts C,et al.Phase Ⅲ trial of capecitabine + oxaliplatin (XELOX) vs 5-fluorouracil (5-FU),leucovorin (LV),and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC).J Clin Oncol,2007,25(18S):4031abstr
  • 9[8]Fuchs C,Marshall J,Mitchell E,et al.Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC:Updated efficacy data.J Clin Oncol,2007,25(18S):4027abstr
  • 10[9]Sanoff HK,Sargent DJ,Campbell ME,et al.N9741:Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (In) combinations for metastatic colorectal cancer (MCRC).J Clin Oncol,2007,25(18S):4067abstr

共引文献99

同被引文献49

二级引证文献40

现代诊断与治疗
2015年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部